News

Celebrating ALS community member Kevin Daly, a new bursary of $2,500 supports the financial needs of post-secondary students Toronto, ON – In partnership with the friends and colleagues of ALS community member Kevin Daly, the ALS Society of Canada (ALS Canada) is pleased…

On April 25, 2023, the U.S. Food and Drug Administration (FDA) approved Qalsody (tofersen) for the treatment of SOD1-ALS under the Accelerated Approval pathway. On May 30, 2024, the European Commission (EC) has granted marketing authorization for Qalsody (tofersen) under…

ALS researchers from around the world continue to build upon existing work and make new discoveries in the hopes of realizing a future without ALS. In the March 2023 Research Update, you’ll learn about the progress researchers have made in…

Nine projects to advance the ALS research landscape funded through ALS Society of Canada and Brain Canada partnership, with support from the Dr. Jean-Pierre Canuel Fund – SLA Québec. Toronto – The ALS Society of Canada (ALS Canada) and Brain…

Today, the Federal Government announced the National Strategy for Drugs for Rare Diseases. We are pleased to see this strategy move forward and hope it will be a significant step in building knowledge and improving access to therapies for people…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada’s advocacy efforts as well as relevant developments within government. Please note that because ALS Canada advocates federally and provincially within Ontario,…

The ALS Society of Canada (ALS Canada) and Brain Canada are investing in the future of innovative scientists who are changing the landscape of amyotrophic lateral sclerosis (ALS) research and treatments in Canada. Together they are contributing a total of…

Today, February 28, marks Rare Disease Day. A day that provides the ALS Society of Canada (ALS Canada) a chance to bring awareness to the disease alongside other potentially lesser-known diseases to work together towards equity in health care, and…